NEW
HAVEN, Conn., Oct. 15,
2024 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today
announced that senior management will be attending the following
investor and medical conferences in October and November.
3rd Chief Commercial Officer Summit
October 23-24, 2024, Philadelphia, PA
Oral
Presentation: Commercial's Role in Clinical Trial
Recruitment
Presentation: October 23, 1:30pm EDT
Trevi
Representative: Farrell Simon, Chief Commercial
Officer
Register here
BIO-Europe
November 4-6,
2024, Stockholm
Sweden
Trevi Representative: Farrell
Simon, Chief Commercial Officer
Register here
Stifel 2024 Healthcare Conference
November 18-19, 2024, New York, NY
Corporate
Presentation: November 18,
11:30am EDT
Trevi
Representatives: Jennifer Good, President and CEO,
Lisa Delfini, Chief Financial
Officer
Register here to watch the live presentation
About Trevi Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy
Haduvio™ (oral nalbuphine ER) for the treatment
of chronic cough in idiopathic pulmonary fibrosis
(IPF) and refractory chronic cough
(RCC). Haduvio is an extended-release
(ER) dual ĸ-opioid receptor agonist
and µ-opioid receptor antagonist that works both
centrally in the brain as well as peripherally in the lungs and has
the potential for a synergistic antitussive effect to
treat chronic cough. Parenteral nalbuphine is not
scheduled by the U.S. Drug Enforcement Agency.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal benefit to patients. Chronic cough affects up to 10% of the
adult population, and Haduvio's expansion into RCC has the
potential to reach patients suffering from moderate to severe
refractory chronic cough. There are also no approved therapies for
RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Barrett
Trevi Therapeutics,
Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-commercial-and-investor-conferences-302275584.html
SOURCE Trevi Therapeutics, Inc.